Activity of Melflufen in RR MM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106): Promising Results in a High-Risk PopulationPaul G. Richardson, Joan Bladé, Xavier Leleu et al.|Clinical Lymphoma Myeloma & Leukemia|2019Cited by 3
PF608 ANCHOR (OP-104): A PHASE 1 STUDY UPDATE OF MELFLUFEN AND DEXAMETHASONE PLUS BORTEZOMIB OR DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS REFRACTORY TO AN IMID OR A PROTEASOME INHIBITORLuděk Pour, Enrique M. Ocio, Yvonne A. Efebera et al.|HemaSphere|2019Cited by 1
ANCHOR (OP-104) Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI): Phase 1 UpdateLuděk Pour, Enrique M. Ocio, Yvonne A. Efebera et al.|Clinical Lymphoma Myeloma & Leukemia|2019Cited by 0
MM-133: HORIZON (OP-106): Melflufen Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody (mAb) – Final Primary AnalysisPaul G. Richardson, María‐Victoria Mateos, Albert Oriol et al.|Clinical Lymphoma Myeloma & Leukemia|2020Cited by 0